ArticleTherapeutic advances in medical oncology2022

A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis.

Hisashi Tanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.